Form 4: InspireMD CCO Granted 453,390 Restricted Stock Shares
Insider Transaction Report
InspireMD's Chief Commercial Officer, Shane Gleason, was granted 453,390 shares of restricted common stock, vesting over three years.
Summary
- Shane Gleason, Chief Commercial Officer of InspireMD, Inc. (NSPR), acquired 453,390 shares of common stock.
- The transaction occurred on January 14, 2026, with a price of $0 per share, indicating a grant of restricted stock.
- These shares will vest in three equal annual installments, with 1/3 vesting on January 14, 2027, January 14, 2028, and January 14, 2029.
- Vesting is contingent upon Mr. Gleason's continued service to the company.
- Following this transaction, Mr. Gleason beneficially owns 1,200,371 shares of common stock.
Sentiment
Score: 7
Explanation: The grant of restricted stock to a key executive is generally a positive signal for executive retention and alignment of interests, though it's a routine compensation event rather than a major strategic announcement.
Positives
- The grant of restricted stock aligns management's interests with long-term shareholder value.
- The vesting schedule encourages retention of a key executive over a three-year period.
Negatives
- No immediate cash inflow for the executive from this grant, as it is restricted stock.
Risks
- Risk of forfeiture if the reporting person's service to the company ceases before the vesting dates.
Future Outlook
The vesting schedule for the restricted stock extends through January 2029, indicating an expectation of continued service from the Chief Commercial Officer over this period.
Industry Context
This type of equity grant is a standard practice in the medical device and biotechnology industries to incentivize and retain key executives, aligning their long-term interests with company performance and shareholder value.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Grant | Shane Gleason granted Michael Lawless, an individual at InspireMD, Inc., a Power of Attorney to prepare and file SEC Forms 3, 4, and 5 on his behalf. This streamlines compliance with Section 16(a) of the Exchange Act. | 01/16/2026 | Enhances efficiency and ensures timely compliance with SEC reporting requirements for insider transactions. |
Stakeholder Impact
- Shareholders: Potential positive impact through improved executive retention and alignment of management interests with long-term company performance.
- Employees: May signal stability in executive leadership.
Next Steps
- Shane Gleason's continued service to InspireMD, Inc. to fulfill vesting conditions.
- Future Form 4 filings upon vesting or other transactions involving these shares.
Key Dates
| Date | Description |
|---|---|
| 01/14/2026 | Date of restricted stock grant to Shane Gleason. |
| 01/16/2026 | Date Power of Attorney was signed and Form 4 was signed by attorney-in-fact. |
| 01/14/2027 | First vesting date for 1/3 of the restricted stock shares. |
| 01/14/2028 | Second vesting date for 1/3 of the restricted stock shares. |
| 01/14/2029 | Third and final vesting date for 1/3 of the restricted stock shares. |
Keywords
InspireMD, NSPR, Shane Gleason, Restricted Stock, Stock Grant, Executive Compensation, Form 4, Insider Transaction, Equity Award, Vesting Schedule
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.